Synmosa Biopharma Corporation (TPEX:4114)
Taiwan · Delayed Price · Currency is TWD 29.60
-0.05 (-0.17%)
Sep 8, 2026, 1:30 PM CST
Synmosa Biopharma Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 6,679 | 6,189 | 5,550 | 5,140 | 4,386 | 3,235 |
Revenue Growth | 11.40% | 11.53% | 7.96% | 17.19% | 35.59% | 6.47% |
Gross Profit Gross Profit Growth | 2,750 | 2,679 | 2,401 | 2,120 | 1,827 | 1,285 |
Operating Income Operating Income Growth | 714.96 | 778.52 | 740.97 | 616.81 | 460.71 | 186.74 |
Net Income Net Income Growth | 827.17 | 821.85 | 684.68 | 594.83 | 799.09 | 303.86 |
Earnings Per Share EPS Growth | 1.53 | 1.54 | 1.37 | 1.23 | 1.71 | 0.64 |
EPS Growth | 8.53% | 12.16% | 11.49% | -28.30% | 166.12% | -53.74% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Generic Drugs Segment Generic Drugs Segment Growth | 5,999 | 5,397 | 4,961 | 4,238 | 3,147 |
Active Pharmaceutical Ingredients Segment Active Pharmaceutical Ingredients Segment Growth | 467.25 | 363.24 | 325.78 | 234.87 | 119.57 |
Intersegment Income Intersegment Income Growth | -276.9 | -210.22 | -146.19 | -86.89 | -31.13 |
Total Total Growth | 6,189 | 5,550 | 5,140 | 4,386 | 3,235 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 2,780 | 2,931 | 1,882 | 1,650 | 1,418 | 988.43 |
Total Debt Total Debt Growth | 3,332 | 2,513 | 2,549 | 2,433 | 3,355 | 3,463 |
Net Cash (Debt) Net Cash Growth | -551.87 | 418.19 | -666.47 | -782.59 | -1,937 | -2,474 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -1.02 | 0.78 | -1.33 | -1.62 | -4.16 | -5.27 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 384.05 | 411.57 | 780.62 | 511.93 | 630.25 | 454.86 |
Capital Expenditures CapEx Growth | -186.41 | -255.44 | -214.52 | -207.04 | -129.3 | -93.06 |
Free Cash Flow Free Cash Flow Growth | 197.64 | 156.14 | 566.1 | 304.89 | 500.95 | 361.81 |
Free Cash Flow Growth | -58.87% | -72.42% | 85.68% | -39.14% | 38.46% | 261.83% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 41.17% | 43.28% | 43.26% | 41.24% | 41.64% | 39.73% |
Operating Margin | 10.70% | 12.58% | 13.35% | 12.00% | 10.50% | 5.77% |
Pretax Margin | 11.65% | 12.92% | 11.88% | 11.70% | 16.53% | 4.76% |
Profit Margin | 12.38% | 13.28% | 12.34% | 11.57% | 18.22% | 9.39% |
FCF Margin | 2.96% | 2.52% | 10.20% | 5.93% | 11.42% | 11.18% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.787 | 0.787 | 0.556 | 0.459 | 0.420 | 0.322 |
Dividend Per Share Growth | 52.92% | 41.67% | 20.97% | 9.28% | 30.37% | 89.42% |
Dividend Yield | 2.65% | 2.69% | 2.01% | 1.65% | 1.34% | 2.37% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 19.40 | 19.77 | 21.18 | 24.72 | 20.05 | 23.09 |
Forward PE | - | 15.36 | 15.63 | 18.08 | 21.79 | 51.28 |
P/FCF Ratio | 80.96 | 104.06 | 25.61 | 48.24 | 31.98 | 19.39 |
PS Ratio | 2.40 | 2.63 | 2.61 | 2.86 | 3.65 | 2.17 |